Company intelligence / Profile preview

Lepu ScienTech

Ownership: Private
Employees: ~314
Development stage: Other

Overview

Lepu ScienTech is the largest manufacturer of congenital heart disease occluder products in China with a 38% market share as of 2021. The company has commercialized multiple generations of occluders and launched the world’s first fully degradable ventricular defect occluder. Clinical results include a 100% surgical success rate and high closure rates for left atrial appendage closure devices, with no ischemic strokes reported post-surgery in trials[8].

Therapeutic areas: Cardiovascular
Modalities: Device
Industry: Implantable Medical Devices

Partnerships

Clinical trial collaborations with Hefei Hospital and other members of the Retained Lepu Medical GroupOEM partnerships via parent company network

Beyond the preview

Go deeper on Lepu ScienTech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lepu ScienTech.

Explore the full profile